Azithromycin Lactobionate Injection

Azithromycin is an azalide antibiotic, and its mechanism of action is to interfere with the synthesis of proteins (without affecting the synthesis of nucleic acids) by binding to the 50s ribosomal subunit of sensitive microorganisms. In vitro tests and clinical studies have shown that azithromycin is effective against the following pathogens: Gram-positive aerobic microorganisms: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, and hemolytic streptococci. Azithromycin has cross-resistance to erythromycin-resistant Gram-positive bacteria. Most fecal streptococci (enterococci) and methicillin-resistant Staphylococci are resistant to this product. Gram-negative aerobic microorganisms: Haemophilus influenzae, Moraxella catarrhalis, and Mycoplasma trachomatis. In vitro tests and clinical studies have confirmed that this product can prevent diseases caused by the avian intracellular mycobacterium complex (composed of avian intracellular mycobacterium and intracellular mycobacterium). This product is ineffective against strains that produce beta-lactamase.

The main ingredient of this product is azithromycin lactobionate, and its chemical name is (2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha;-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-beta;-D-xyl-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one lactobionate. Molecular formula: C38H72N2O122C12H22O12, molecular weight: 1465.59

This product is a colorless clear liquid.

This product is suitable for the following infections caused by sensitive pathogens: 1. Community-acquired pneumonia caused by Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Staphylococcus aureus or Streptococcus pneumoniae, which requires intravenous administration first. 2. Pelvic inflammatory disease caused by Chlamydia trachomatis, Gonorrhea, Mycoplasma hominis, which requires intravenous administration first. If anaerobic infection is suspected, anti-anaerobic antibiotics should be used in combination.

Add this product to 250ml or 500ml of 0.9% sodium chloride injection or 5% glucose injection to make the final azithromycin concentration of 1.0-2.0mg/ml, intravenous drip, the drip time is: concentration of 1.0mg/ml, drip for 3 hours; concentration of 2.0mg/ml, drip for 1 hour. For the treatment of community-acquired pneumonia, the adult dosage is 0.5g each time, once a day, for at least 2 consecutive days, followed by switching to oral azithromycin oral preparations 0.5g/day, and the treatment is 7-10 days as a course of treatment. The time to switch to oral treatment should be determined by the doctor based on clinical response. For the treatment of pelvic inflammatory disease, the adult dosage is 0.5g each time, once a day. After 1 or 2 days of medication, switch to azithromycin oral preparations 0.25g/day, with 7 days as a course of treatment. The time to switch to oral treatment should be determined by the doctor based on clinical response. If anaerobic infection is suspected, anti-anaerobic drugs should be used in combination.

1. Common adverse reactions of this product include: 1. Gastrointestinal reactions: diarrhea, nausea, abdominal pain, loose stools, vomiting, etc.; 2. Local reactions: pain at the injection site, local inflammation, etc.; 3. Skin reactions: rash, itching, etc.; 4. Other reactions: such as anorexia, dizziness or dyspnea, etc. 2. This product may also cause the following reactions: 1. Digestive system: indigestion, flatulence, oral candidiasis, gastritis, etc.; 2. Nervous system: headache, drowsiness, etc.; 3. Allergic reactions: bronchospasm, etc.; 4. Other reactions: abnormal taste, etc.; 5. Laboratory tests: increased serum ALT, AST, creatinine, LDH, bilirubin and alkaline phosphatase, decreased white blood cell, neutrophil and platelet counts.

It is contraindicated in patients who are allergic to azithromycin, erythromycin or other macrolide antibiotics.

Precautions for children: The safety of this product for children is not yet clear. Precautions for pregnancy and lactation: Use with caution for pregnant and lactating women. Precautions for the elderly: Not yet clear.

Close observation of patients is recommended when azithromycin is used with the following drugs: Digoxin: Increases digoxin levels. Ergotamine or dihydroergotamine: Symptoms of acute ergot toxicity are severe peripheral vasospasm and dysesthesia (pain to touch). Triazolam: Increases the pharmacological effect of triazolam by reducing its degradation. Cytochrome P450 system metabolites: Increases serum levels of carbamazepine, terfenadine, cyclosporine, cyclohexylbarbital, phenytoin, etc.

Keep in a dark, airtight container in a cool place.

Based on azithromycin, 2.5ml: 0.125g

18 months

CSPC OUYI Pharmaceutical Co., Ltd.

• Founded in:

  2001-03-29

• Address:

  No. 88, Yangzi Road, Shijiazhuang Economic and Technological Development Zone

• Tax NO.:

  91130100601289268L

• Registered Funds:

  298 million yuan

• Website:

  Log in to view

• Email:

  Log in to view